A small peptide to protect brain connections in Alzheimer's-related dementias
Official title: A Synapse-Protecting Small Peptide to Treat a-Syn/Tau Mixed Proteinopathies in Alzheimer's Disease Related Dementias (ADRD)
Funded at Creative Bio-Peptides, INC. · NIH-11158833 · Data updated 2026-11-12
This study is testing a new treatment for older adults with Alzheimer's-related dementias that targets multiple harmful proteins in the brain to help protect memory and thinking skills.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Creative Bio-Peptides, INC. NIH-funded |
| Lab location | 1 site (Potomac, United States) |
| Project start | September 15, 2021 |
| Project end | April 30, 2026 |
| Funding year | 2025 |
| Award (this year) | $1,118,107 |
| NIH project number | 5R44AG074715-03 |
| Project ID | NIH-11158833 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals aged 65 and older who are experiencing symptoms of Alzheimer's disease-related dementias.
✕Less likely to help
Patients under the age of 65 or those with other forms of dementia not related to mixed proteinopathies may not benefit from this research.
What this research studies
This research investigates a novel small peptide aimed at treating mixed proteinopathies, specifically targeting the co-occurrence of alpha-synuclein, amyloid beta, and tau proteins in Alzheimer's disease-related dementias. The approach focuses on mitigating synapse loss, which is crucial for memory and cognitive function, by using chemokine receptor antagonists that have shown promise in previous studies. By addressing multiple underlying causes of neurodegeneration simultaneously, the research aims to provide a more effective treatment strategy for patients over 65 suffering from these conditions.
Why it matters
Potential benefit: If successful, this research could lead to a new treatment that slows down or prevents cognitive decline in patients with Alzheimer's-related dementias.
How similar studies have gone: Previous research has indicated that targeting multiple proteinopathies can be an effective strategy, suggesting potential success for this novel approach.
Where this research is happening
-
Creative Bio-Peptides, INC.
Potomac, United States Active
Researchers
- Principal investigator: Ruff, Michael R — Creative Bio-Peptides, INC.
- Study coordinator: Ruff, Michael R
Related research
Other NIH-funded projects on the same topics.
-
Understanding how brain activity changes may drive Alzheimer’s disease progression in a mouse model
Researchers are testing how changes in brain signals and protein cleanup processes affect the development of Alzheimer’s disease in mice.
-
Thiamine-boosting therapy for Alzheimer’s: understanding how benfotiamine may reduce harmful AGE in DP patients
A medication-based approach using high-dose vitamin B1 (benfotiamine) is studied to help people with Alzheimer's by reducing harmful sugar-related molecules.
-
Non-invasive tears biomarker for early Alzheimer's in LMICs
A low-cost, tear-based biomarker approach aims to detect early Alzheimer’s disease in older adults in Peru and similar settings.
-
Turning APOE4 into protective APOE2 or APOE3Christchurch to help with Alzheimer’s
A patient-facing explanation of a treatment idea that aims to change a genetic risk factor for Alzheimer's disease in the brain.
-
Telomerase in Alzheimer’s Disease: how aging biology could influence memory and brain health
Researchers are exploring a new brain-aging mechanism linked to telomerase, with potential to slow or modify Alzheimer’s disease in people and improve cognitive function.
-
Biomarkers of Alzheimer’s Disease: Sensory, Motor, and Cognitive Clues
Researchers are testing simple sensory and movement tasks to find early signs of Alzheimer’s disease so they can diagnose and treat people sooner.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.